News Releases

Armetheon to Participate in Two Events During Week of JP Morgan Healthcare Conference

MILPITAS, Calif., Jan. 5, 2016 /PRNewswire/ -- Armetheon, Inc., a specialty pharmaceutical company developing novel small molecule drugs for cardiovascular diseases, today announced that Dr. Sanjay Kakkar, Chief Executive Officer, will present at two events during the week of the 34th Annual JP Morgan Healthcare Conference in San Francisco.

Armetheon Logo

Dr. Kakkar will participate in the East/West CEO Conference on the panel entitled, "IPOs: 2016 Predictions," on Sunday, January 10, 2016 at 11:00a.m. Pacific Time. The conference will be held at the Four Seasons Hotel in San Francisco, CA.

In addition, Dr. Kakkar will present a company overview at Biotech Showcase 2016 at the Parc 55 Hotel on Tuesday, January 12th at 10:45a.m. Pacific Time in San Francisco, CA.

About Armetheon

Armetheon, Inc., is a privately held, specialty pharmaceutical company developing and commercializing innovative medicines addressing major unmet needs in cardiovascular disease, initially in thrombosis. Armetheon focuses on improved therapies with the goal of increased efficacy, safety, and utility, targeting specialty markets with clearly defined regulatory pathways. Armetheon's lead candidate, tecarfarin, is being investigated for use as a Vitamin K Antagonist and is currently in Phase 3 development for the prevention and management of thrombosis. For more information:

For Armetheon:
Heather Lake, Director of Corporate Development
+1 650-646-3898, ext. 121

For Media: Justin Jackson
For Investor Inquiries: Ami Bavishi
Burns McClellan
+1 212-213-0006


SOURCE Armetheon, Inc.